DOTATOC：一种用于受体介导放射性核素治疗的强大新工具。
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
作者信息
Otte A, Jermann E, Behe M, Goetze M, Bucher H C, Roser H W, Heppeler A, Mueller-Brand J, Maecke H R
机构信息
Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland.
出版信息
Eur J Nucl Med. 1997 Jul;24(7):792-5. doi: 10.1007/BF00879669.
This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the beta-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTATOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1. 9-fold lower with 111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.
本研究首次成功使用了一种肽类载体DOTATOC，其用发射β射线的放射性同位素钇-90标记，用于治疗一名患有未知原发部位神经内分泌癌且生长抑素受体阳性腹部转移瘤的患者，实现了肿瘤反应和症状缓解。此外，新物质DOTATOC用诊断性化学类似物铟-111标记，并在3例经组织病理学证实为神经内分泌腹部肿瘤的患者中研究其诊断敏感性，并与市售的奥曲肽扫描进行比较。在所有患者中，111In-DOTATOC的肾与肿瘤摄取比值（每像素计数）平均比奥曲肽扫描低1.9倍。DOTATOC可能是神经内分泌肿瘤管理中一种潜在的新型诊断和治疗药物。
Zotero 插件